Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Academic collection

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Major advances in intensive care medicine have allowed great improvements in the outcome of critically ill patients over the last decades, with nowadays a large proportion of patients surviving the acute insult. However, many of these patients report decreased quality of life after ICU discharge, due to persistence of complications acquired during the ICU stay. As a result, the focus of clinicians and researchers has shifted more towards therapies that may prevent the development or reduce the burden of critical illness-related morbidity. Artificial nutrition is one of the cornerstones of such so-called supportive therapies, which are specifically aimed at enhancing recovery of patients while reducing the risk of ICU-related complications. In the last 10 years, several large RCTs have tested various modalities of the use of artificial nutrition. Strikingly, however, when combining all available evidence, early enhanced feeding was shown not to be beneficial for ICU patients, and was even harmful in some of the trials. Indeed, early enhanced nutrition by supplementing insufficient enteral nutrition with parenteral nutrition (Early-PN) was shown to delay recovery and to increase the risk of acquiring complications like muscle weakness in ICU, as compared with accepting an early macronutrient deficit by not initiating supplemental parenteral nutrition during the first week in ICU (Late-PN). This is an important finding, as ICU-acquired weakness hampers the recovery of critical illness, and also does not recover swiftly and fully after the critical illness itself has resolved. Thereby, ICU-acquired weakness affects mortality and quality of life up to years after discharge from the ICU. Therapies targeting ICU-acquired weakness are currently still scarce and insufficient, and are limited to preventive measures, such as not initiating parenteral nutrition during the first week in ICU. From a mechanistic viewpoint, the increased risk of muscle weakness with Early-PN as compared with Late-PN has been explained by the inability of Early-PN to suppress catabolism and its suppressive effect on autophagy, which is a cellular quality control mechanism that is crucial for recovery of organ failure in critical illness. Nutrition-induced suppression of ketogenesis may also have played a role, as exogenous administration of ketones in mice was shown to protect against sepsis-induced muscle weakness.The general aim of this doctoral thesis was to gain further mechanistic insight into the observed clinical benefits of accepting an early macronutrient deficit (Late-PN) in critically ill patients as compared with early full feeding (Early-PN), with a focus on ICU-acquired weakness, and to explore novel nutritional strategies for ICU patients, which in the future may aid in preventing the development of ICU-acquired weakness.In a first part, we demonstrated that Late-PN suppressed the growth hormone axis in critical illness as compared with Early-PN. Serum concentrations of growth hormone and IGF-I were lower and those of IGFBP1 were higher when accepting an early macronutrient deficit, whereas IGFBP3 was not affected. Lower growth hormone concentrations with this intervention were explained by a decrease in its non-pulsatile secretion, whereas pulsatile secretion was unaffected. The further suppression of the growth hormone axis statistically appeared to be an undesirable side effect of Late-PN and can thus be considered a "price to pay" for the benefits of Late-PN as compared with Early-PN, as these benefits were attenuated but not annihilated by its effect on the growth hormone axis. Whether the growth hormone axis recovers after critical illness, whether changes in the growth hormone axis may play a role in the persistence of ICU-acquired weakness and whether pharmacological reactivation of the growth hormone axis in the context of Late-PN may further augment the observed clinical benefits thereof remains to be investigated.In a second part, we demonstrated that DNA methylation is altered in muscle of critically ill patients as compared with volunteers who had never been critically ill but had similar comorbidities as the patients. DNA methylation alterations occurred at 565 individual CpG sites that were associated with 400 unique genes, many of which were identified as highly relevant for muscle structure, muscle function and/or muscle weakness. We also identified two hypomethylated regions in the promotor regions of the HIC1 and NADK2 genes, which play important roles in muscle regeneration and postsynaptic acetylcholine receptors, and in mitochondrial processes, respectively. These findings suggest that aberrant DNA methylation alterations in muscle of critically ill patients may contribute to the development and the persistence of ICU-acquired weakness, which requires further investigation. Importantly, if this would prove to be the case, therapies targeting aberrant DNA methylation may have great potential in the prevention and/or treatment of ICU-acquired weakness.In a third part, we completed the first step in the design of a fasting-mimicking diet for the ICU. Indeed, we were able to demonstrate that prolonged critically ill patients develop a metabolic fasting response after a 12-hour nutrient interruption, as illustrated by significant increases in serum concentrations of bilirubin and the ketone body beta-hydroxybutyrate, and decreases in insulin requirements to maintain normoglycemia and in serum IGF-I. The documented fasting response is an important finding, as the ability of showing such a response during critical illness has long been debated, and it allows progression to a next step in designing a fasting-mimicking diet. This intervention, consisting of alternating blocks of 12 hours of feeding and 12 hours of fasting, based on our results, will be tested for its ability to enhance autophagy and ketogenesis. As the present study demonstrated that autophagic markers in blood samples were largely unaffected by fasting in patients and matched healthy subjects, and thus may not be a good surrogate of autophagy at the level of other tissues, autophagy will be studied directly at the level of muscle biopsies. If this follow-up trial would be successful, the ultimate goal of this project is to test the impact of the designed fasting-mimicking diet on clinical outcomes including ICU-acquired weakness in a large multicenter randomized trial.In a fourth part, we focused on GDF15, which is a cellular stress marker that has been shown to induce aversive responses to nutrition when there is low nutritional need or when macronutrients cannot be metabolized, thus possibly indicating whether a patient is ready for enhanced artificial nutrition. Serum GDF15 concentrations were elevated throughout critical illness, a response which was not affected by randomization to Early-PN versus Late-PN, but was more pronounced in ICU non-survivors than survivors. Higher GDF15 concentrations upon ICU admission were independently associated with worse outcome of critical illness, including a higher risk of ICU-acquired muscle weakness. Higher concentrations of GDF15 were significantly but weakly associated with gastrointestinal intolerance, and GDF15 concentrations upon ICU admission did not appear to discriminate patients at low versus high risk of Early-PN-related complications. Thus, from our findings, the potential of GDF15 as a "ready-to-feed indicator" for the individual patient appeared limited. However, the dramatically elevated GDF15 levels during critical illness may explain the low appetite and gastrointestinal intolerance that are often seen in critically ill patients. Future research should focus on investigating the relation between GDF15 and gastro-intestinal intolerance, and on finding other biomarkers that can be used as ready-to-feed indicator.In conclusion, this PhD project provided valuable insight with regard to the further optimization of nutritional therapies to improve outcome of critically ill patients, with a particular focus on prevention of ICU-acquired weakness. The research presented in this thesis also raised numerous important new questions for further investigations, with perspectives for further improvement of the care and outcome of critically ill patients.

Academic collection

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Protein kinases and phosphatases are antagonistically acting enzymes that cooperate to control the speed, amplitude and specificity of phosphorylation signals in numerous cellular processes, including mitosis. Early mitotic events are characterized by bulk phosphorylation of specific proteins by kinases such as CDK1/Cyclin B and Aurora B. The mitotic exit depends on protein phosphatases, mainly PP1 and PP2A, which remove phosphate groups from mitotic phosphoproteins and re-establish the interphase state. We are interested in the antagonistically acting enzymes Aurora B and PP1:RepoMan. During prometaphase, PP1-RepoMan dephosphorylates Histone 3 at Threonine 3 along the chromosome arms to promote the centromeric enrichment of Aurora B. This is dynamically opposed by CDK1-mediated phosphorylation of the PP1-binding domain of RepoMan and by Aurora B itself, which inhibits RepoMan binding to histones. The reciprocal regulation between RepoMan and Aurora B results in the enrichment of Aurora B at the centromeres, where the kinase is maximally active and prevents erroneous kinetochore-microtubules attachments. During anaphase, Aurora B localizes to the spindle midzone and PP1-RepoMan is massively recruited to the chromosomes, where it catalyzes the bulk dephosphorylation of mitotic-exit substrates. Aurora-B overexpression in cancer is often associated with chromosome mis-segregation. The main molecular pathways that regulate Aurora-B abundance in cells are well understood. Moreover, small molecule inhibitors of Aurora B are being used in clinical trials to treat cancer patients. RepoMan is also frequently overexpressed in human cancers. However, it is not known if RepoMan and Aurora B are co-overexpressed and, importantly, which mechanisms control RepoMan levels in tumor cells. By using publicly available datasets, we found that RepoMan and Aurora-B co-overexpression correlated with tumor aggressiveness in some types of tumors. Then, by using biochemical approaches we showed that RepoMan levels oscillate similarly to Aurora B, increasing in G2/M phase and declining at the mitotic exit and in interphase. Interestingly, both RepoMan and Aurora B mRNA levels are controlled by the transcription factor FOXM1 and their protein downregulation is mainly controlled by ubiquitin-mediated proteasomal degradation. During mitotic exit and early G1, RepoMan and Aurora B are both targeted by the ubiquitin ligase APC/C-CDH1, while during G1/S phase their levels are kept low by E3 complex SCF-FBXW7. The existence of a cell-cycle co-regulation of RepoMan:Aurora B pair indicate that cells should benefit from having balanced levels of the two enzymes. Mathematical modeling revealed that co-oscillations in RepoMan:Aurora B level generate a dynamic bistable system that is more robust to stochastic changes. A theoretical model also predicted that cells with high RepoMan concentration are more vulnerable to treatment with Aurora-B inhibitors, which was validated experimentally. We speculate that tumor cells use multiple ways to keep the balance between RepoMan and Aurora B in order to proliferate with mild/advantageous levels of aneuploidy. Disturbing this balance, chemically or genetically, might be a novel and more specific therapeutic approach for the treatment of cancer patients.

Academic collection

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

A healthy mouth makes for a confident laugh and ensures us that we can enjoy that tasty steak or juicy apple. However, oral diseases can have consequences even beyond the mouth. Lately, there is a growing interest for the link between gum health and several systemic diseases. However, despite its far-reaching effects and a focus on prevention, oral health problems are still affecting the majority of the population worldwide. There is thus a need for alternative and/or complementary therapies in addition to the current preventive and therapeutic strategies.In a healthy mouth, there is a symbiotic relationship, a dynamic balance between the oral microbiome, the host and the environment. A disturbance of this homeostasis can lead to an overgrowth of pathogenic bacteria. Traditional therapies focus on the reduction and elimination of the bacterial load. More recently, in line with previous gastrointestinal research, it was suggested that administering live, 'beneficial' microorganisms (probiotics) could be an alternative for restoring this homeostasis.At the start of this PhD, the interest in using probiotics for a healthier mouth was already growing. Although the research was limited at that moment, the available results were promising (Chapter 1). However, there were still many unanswered questions concerning the ideal probiotics for oral health, uninvestigated applications, etc.The most studied probiotic for oral health is, to the best of our knowledge, a dual strain lactobacilli probiotic containing Lactobacillus reuteri DSM 17938 and Lactobacillus reuteri ATCC PTA 5289. Research showed the added value of this product in the prevention of caries and as a complementary therapy in the non-surgical therapy of periodontitis. We demonstrated for the first time the additional effect of this product to re-instrumentation of residual pockets in chronic periodontitis patients. However, we failed to show an added effect after the administration of this product compared to a placebo as complementary treatment to the non-surgical debridement of initial peri-implantitis sites (Chapter 2).Lactobacilli are of course only one example of microorganisms to which probiotic capacities are attributed. The third chapter of this thesis investigated the use of a streptococci probiotic and the clinical effects of oral health products containing Bacillus species. However, both studies could not show any added effects of these probiotics for the examined indications. The first trial failed to show better treatment results of a Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145 probiotic compared to a placebo used for 3 months after scaling and root planing in chronic periodontitis patients. In addition, the second study did not demonstrate improved clinical parameters of the usage of Bacillus species based probiotics compared to a placebo in gingivitis patients.Combining the studies in this thesis and the current literature, one can conclude that probiotics can be an interesting, alternative strategy for improving oral health. However, it is important to note that probiotic effects depend on strain, concentration, mode of delivery and, moreover, are indication-specific. However, it is not clear what the underlying mechanisms of the seen clinical benefits of certain probiotics are.In conclusion, there appear to be different applications for probiotics in dentistry, but more fundamental research is needed to use them in a targeted way, which in turn will lead to more effective usage of time and resources in clinical research.

Academic collection

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Academic collection